Osimertinib and Selinexor Team Up Against Aggressive T-Cell Leukemia in Preclinical Study
A preclinical study reports that the EGFR inhibitor osimertinib and the XPO1 inhibitor selinexor synergistically deplete c-MYC and trigger nucleolar ...
A preclinical study reports that the EGFR inhibitor osimertinib and the XPO1 inhibitor selinexor synergistically deplete c-MYC and trigger nucleolar ...
An FDA-approved nuclear export inhibitor killed lab-grown pediatric glioma cells carrying BRAFV600E and, combined with a MEK inhibitor, suppressed regrowth ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.